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ABSTRACT OF DISSERTATION

STUDIES ON THE ROLE OF ACID SPHINGOMYELINASE AND CERAMIDE
ON THE REGULATION OF TACE ACTIVITY AND TNF PRODUCTION BY
MACROPHAGES

Acid Sphingomyelinase (ASMase) activity has been proposed to mediate
LPS signaling in various cell types. This study shows that in macrophages,
ASMase is a negative regulator of LPS-induced TNF secretion. ASMasedeficient (asm-/-) mice and isolated peritoneal macrophages produce several fold
more TNF than their wild-type (asm+/+) counterparts when stimulated with LPS.
The mechanism for these differences however is not transcriptional but posttranslational.
The TNF converting enzyme (TACE) catalyzes the maturation of the
26kD precursor (proTNF) to the active 17kD form (sTNF). In mouse peritoneal
macrophages, the activity of TACE rather than the rate of TNF mRNA synthesis
was the rate-limiting factor regulating TNF production. Substantial portion of the
translated proTNF was not processed to sTNF; instead it was rapidly
internalized and degraded in the lysosomes. TACE activity was 2 to 3 fold higher
in asm-/- macrophages as compared to asm+/+ macrophages and was suppressed
when cells were treated with exogenous ceramide and SMase. In asm-/- but not
in asm+/+ macrophages, indirect immunofluorescence experiments revealed
distinct TNF-positive structures in close vicinity of the plasma membrane. Asm-/cells also had higher number of EEA1-positive early endosomes. Co-localization
experiments that involved inhibitors of TACE and/or lysosomal proteolysis
suggest that in asm-/- cells a significant portion of proTNF is sequestered within
the early endosomes, and instead of undergoing lysosomal proteolysis it is
recycled to the plasma membrane and processed to sTNF.
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CHAPTER ONE

Introduction
A. Regulation and biological effects of Tumor Necrosis Factor  in health
and disease
Tumor necrosis factor  (TNF)1 belongs to a class of proteins, called
cytokines, which are important mediators in host response to stresses such as
infection, inflammation, and injury. It is highly conserved among mammals with
78% identity between human and mouse protein.
Since it was identified more than 30 years ago, several thousand papers
looking mostly at biological effects of TNF in variety of cell types and animal
models have been published. TNF was initially described as a factor capable of
killing tumor cells in vitro and of causing hemorrhagic necrosis of transplantable
tumors in mice [1]. Later studies revealed that it has a broad spectrum of
biological activities including stimulation of neutrophil adhesion and activation,
chemotaxis, phagocytosis, and vascular permeability to name of few [2-5].
1

Abbreviations: ADAM, A Disintegrin and metalloproteinase; ANOVA,
Analysis of Variance; ASMase, Acid sphingomyelinase; AP-1, Activator protein-1;
EEA1, Early endosomal antigen 1; ELISA, Enzyme-linked immunosorbent assay;
ERK, Extracellular signal regulated kinase; FITC, Fluorescin isothiocyanate;
HPLC, High pressure liquid chromatography; IL-1, Interleukin-1; i.p.,
intraperitoneally; IRAK, Interleukin-1 receptor-associated kinase; JNK, c-Jun
terminal kinase; LBP, LPS binding protein, LPS, Lypopolysaccharide; MAPK,
Mitogen-activated protein kinase; MyD88, Myeloid differentiation factor 88; NBD,
6-((N-(7nitrobenz-2-oxa-1,3-diazol-4-yl))amino)-C6; NF-B, Nuclear factor B;
NH4Cl, Ammonium chloride; NSMase, Neutral sphingomyelinase; PGE2,
Prostaglandin E2; PMA, Phorbol 12 myristate 13 acetate; RA, Rheumatoid
arthritis; RFU, Relative fluorescent units; SDS-PAGE, Sodium dodecyl sulfate
polyacrylamide gel electrophoresis;
siRNA, Small inhibitory RNA; SM,
sphingomyelin; SPT, serine palmitoyltransferase; S-1-P, sphingosine-1phosphate; TACE, TNF converting enzyme; TAK1, Transforming growth factor-activated kinase; TGF, Transforming growth factor ; TLR, Toll-like receptor;
TNF, Tumor necrosis factor ; TRAF6, Tumor necrosis factor-associated factor;
TRITC, Tetramethylrhodamine isothiocyanate.
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Tissue and cellular effects of TNF

TNF has a central role in the initial host response to infection and it is a
key player in the regulation of immune homeostasis. Studies in TNF transgenic
and TNF knockout mice have demonstrated that TNF has important
immunomodulatory functions both in vivo and in vitro. It is required not only for
the initial priming phase of antigen specific immunity and effector functions, but
also for the resolution phase [6]. Furthermore, studies in TNF knockout mice
show that TNF plays a critical role in germinal centers formation in the spleen
[7]. These structures are important for antibodies isotype switching, affinity
maturation and memory formation  thus linking TNF to the adaptive immunity.
TNF also has diverse effects upon the neutrophil population ranging from
stimulation of neutrophil release from bone marrow to regulation of neutrophil
chemotaxis [4], degranulation [2], superoxide production [8], and lysozyme
release [2]. TNF stimulates the phagocytic potential of macrophages and the
production of a number of pro- and anti- inflammatory mediators such as IL-1,
IL-6, PGE2, etc [9] [10].
TNF can induce a wide variety of biological effects and has a profound
impact on the function of many cell types and tissues, which do not belong to the
immune system. The incubation of endothelial cells with TNF increases
vascular permeability [11]. Chronic delivery of TNF has been linked to the loss
of total body protein and significant histologic changes within the liver [12].
Furthermore, in vivo studies indicated that sub-lethal doses of TNF affect the
adipose tissue and elevate serum levels of triglycerides and free fatty acids [13,
14].

Dysregulation of TNF and Diseases

In a healthy state, TNF is produced in response to various stimuli mainly
by macrophages. However, the onset of many diseases is correlated with the
2

induction of TNF production by various cells that normally do not produce it.
Interestingly, however, the important questions of how it is regulated and what
makes the difference between its beneficial and deleterious effect are not yet
answered. Nevertheless, there are three major factors which appear to be of
significant importance: concentration, duration and location, or combinations of
them.
TNF is not usually detectable in young and healthy individuals, but its
levels sharply increase during inflammatory response. Importantly, its secretion is
transient and TNF is quickly and efficiently cleared when the pathogen is
neutralized. The importance of the strict regulatory mechanisms sensing and
maintaining proper TNF levels is underlined by the observation that pathological
dysregulation of TNF production/clearance occurs in many diseases.
Uncontrolled systemic release of TNF is a hallmark of septic shock and it
is tightly linked to the morbidity and mortality of the disease [15, 16]. Unlike
systemic inflammation, TNF in rheumatoid arthritis (RA) is produced locally, but
its secretion persists over a long period of time. Similarly, local but chronic
production of TNF is implicated in the pathology of Crohn’s disease and
asthma. The cause-effect relationship between TNF and the onset or the
severity of the disease is supported by experimental data showing that
overexpression of TNF in mice results in chronic inflammatory arthritis and
inflammatory bowel disease [17, 18].
TNF is mostly discussed in the context of the innate immunity but it can
also be produced by cells unrelated to the immune system, such as adipocytes,
smooth and cardiac muscle cells, endothelial cells, osteoclasts, etc (Fig.1.1).
Mounting evidence suggests that obesity promotes a state of chronic
inflammation with elevation of TNF, which contributes to insulin resistance and
type 2 diabetes. Although it is not entirely clear what the trigger of TNF
production is for the prediabetic state, it might be nutritionally regulated.
Dysregulation of TNF production and chronic inflammation are also a
hallmark of physiologic process such as aging [19]. TNF is one of the prime
signals inducing cellular apoptosis in muscle, and is therefore an important
3

contributor to muscle waste in the elderly [20, 21]. Elevated levels of TNF are
also evident in a large number of neurological disorders including: traumatic brain
injury, multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease; but
whether TNF signaling actively contributes to, or limits neuronal injury in these
disorders has yet to be established [22-25].
On certain occasions chronic elevation of TNF may prove beneficial in
suppressing the active stage of a disease. For instance, the effects of TNF
blockade, which is beneficial in a number of diseases has been assessed in
individuals with multiple sclerosis and was found to worsen the disease [26, 27].
Furthermore, immunosuppressive effects of TNF might explain the reports of
rare demyelinating syndromes in patients after prolonged TNF blockade [28], as
well as the development of antinuclear antibodies and lupus syndromes in a
significant proportion of patients with RA receiving anti-TNF therapy [29].
At the cellular level, TNF activates NF-B, JNK, ERK, and caspases,
which are part of signaling pathways leading to cell survival, proliferation, and
apoptosis. It has been suggested that acute and chronic TNF responses may
be determined at the biochemical level by the complex interactions between
these pathways [30]. For example, TNF plays an important role in immune
homeostasis including lymphocyte activation, survival, and differentiation.
Inhibition of the caspase pathway by sustained activation of NF-B will generate
a survival signal, which is critical for rapid immune responses to foreign
pathogens.

On the other hand, inappropriate expansion of self-reactive

lymphocyte population at sites of inflammation would clearly be detrimental. The
factors which act as a switch between pro-survival and pro-apoptotic pathways
still remain mostly unknown. However, a study in human fibroblasts points at NFB as such a factor, demonstrating that prolonged stimulation with TNF impairs
IB re-synthesis, resulting in continued activation of NF-B response [31].

B. Sphingolipids metabolism and biological effects

4

Sphingolipids are essential components of all biological membranes, but
are also well-recognized active biomolecules which mediate and modulate
diverse signaling pathways. Sphingosine is one of the first sphingolipids which
was identified, and has been implicated in the regulation of cell cycle,
cytoskeleton reorganization, endocytosis, and apoptosis [32]. Even more
attention has been given to two other sphingolipids, ceramide and sphingosine-1phosphate (S-1-P), which often have antagonistic effects: ceramide regulates
many cell-stress responses including apoptosis and cell senescence [33, 34],
while S-1-P has a crucial role in cell survival and cell migration [35]. Among these
bioactive sphinglipids, ceramide is produced in the largest amount and is
considered the central molecule in sphingolipid biosynthesis and catabolism. The
two main metabolic pathways for generation of ceramide are (i) the de novo
synthesis in the endoplasmic reticulum, and (ii) the turnover of sphingomyelin
(SM) either at the plasma membrane or in the endosomal/lysosomal
compartment (Fig. 1.2). A number of agonists have been shown to activate these
pathways leading to transient elevation in ceramide. The magnitude and
temporal pattern of ceramide accumulation is further influenced by the activity of
ceramidases, SM synthases, ceramide kinase, and glucosyl/galactosyl ceramide
synthases.

These enzymes catalyze the conversion of ceramide to other

sphingolipids, and some agonists seem to coordinately regulate both the
ceramide production and turnover.
The de novo pathway for synthesis of ceramide takes place in the
endoplasmic reticulum and starts with condensation of palmitoyl-CoA and serine.
This is the rate-limiting step catalyzed by serine palmitoyltransferase (SPT),
which produces 3-ketosphinganine. Additional reactions of reduction followed by
acylation generate relatively inactive dihydroceramide, which is converted by
desaturase to the bioactive ceramide. The newly generated ceramide is actively
transported to the Golgi apparatus, where it serves as a rate-limiting substrate in
the synthesis of complex sphingolipids, like SM and glycosphingolipids.
The alternative pathway for ceramide generation is the hydrolysis of
sphingomyelin by a group of enzymes known as sphingomyelinases (SMases).
SMase activities with neutral and acidic pH optima are found in most mammalian
5

cells, and an enzyme active in alkaline pH is localized in the intestinal wall.
Currently, research is focused on 4 genes encoding different mammalian
SMases: smpd1 encodes two forms of acidic SMase, one associated with the
endosomal/lysosomal compartment (ASMase), and a second one found in the
plasma and the conditioned medium of stimulated cells (SSMase). smpd2 and
smpd3 encode the Neutral SMase 1 (nSMase1) and 2 (nSMase2), both of which
are Mg2+-dependent but differ in their sub-cellular localization and role in
signaling. The recently cloned smpd4, is suggested to encode a novel form of
NSMase, nSMase3 that is found predominantly in skeletal muscle and heart.
ASMase is a 72kD glycoprotein with a 57kD peptide core. The processing
of the carbohydrate moieties within the Golgi is critical for sub-cellular trafficking
of this enzyme. For example, the addition of mannose-6-phosphate residues is
essential for lysosomal localization of ASMase. Alternative carbohydrate
processing within the Golgi can result in targeting the enzyme to the secretory
pathway [36, 37].
ASMase was first purified from human brain, and was found to have
optimal pH of 5.0 [38]. Based on trypsin digestion and mass spectrometric
analysis a model was proposed, according to which the enzyme has three
domains: an activator domain, followed by a proline rich domain, and a catalytic
C-terminal domain. Both the lysosomal and the secretory forms require divalent
cation Zn2+ for proper activity [36]. Many lipids were also found to influence
ASMase activity. For example, the presence of fatty acids, mono-, di-, and triacylglycerols as well as phosphatidylinositol has been found to activate ASMase
and stimulate sphingomyelin hydrolysis [39]. On the other hand, ceramide-1phosphate, S-1-P, and phosphatidylinositol-4,5-bisphosphate inhibit ASMase [40,
41]. Interestingly, cholesterol, which physically associates with sphingomyelin
within lipid rafts, also inhibits ASMase [42]. Furthermore, the activation of
ASMase leads not only to sphingomyelin hydrolysis but also cholesterol depletion
[43]. Accordingly the loss of ASMase activity causes accumulation of both
sphingomyelin and cholesterol.

6

ASMase is activated by numerous stimuli including TNF, LPS,
Fas/CD95, radiation, and ischemia, and in a large variety of cell types [44-49]
(Fig.1.3). In many cases, the activation of ASMase is associated with its
translocation to the plasma membrane [50]. The cellular mechanisms regulating
ASMase activity and localization remain unclear, although it has been suggested
that phosphorylation of Ser508 is required for ASMase translocation to the plasma
membrane after UV irradiation of MCF-7 cells [51]. Furthermore, Jin et al
demonstrated that lysosomal trafficking and fusion with the plasma membrane is
linked to the formation of lipid rafts in endothelial cells [50]. Lipid rafts have been
implicated in receptor clustering and initiation of signal transduction via death
receptors such as TNFR and CD95 [44, 46, 52]. Data coming from the inhibition
of ASMase activity (using siRNA, or pharmacologic inhibitors or using NPD cells
or knockout mice) have shown that this enzyme is indispensable for the
execution of apoptotic response in variety of cell types. For instance, ASMase
knockout mice were protected against endothelial apoptosis and had higher
survival rate in response to LPS [53]. Furthermore, studies in fibroblasts from
Niemann–Pick disease type A patients, who exhibit deficiency of ASMase and
hepatocytes from ASMase knockout mice show that ASMase activation is
required and sufficient for CD95 induced apoptosis [46]. ASMase is also
important for tumor suppression and sensitivity to radiation therapy. Tumors
growth progresses faster in ASMase knockout mice compared to the wild-type
controls.
The hydrophobic nature of ceramide limits its diffusion in the water-based
cellular environment, and therefore its action is limited to the location of its
generation, mainly endolysosomes and lipid rafts. Only a few direct targets of
ceramide have been described, which can potentially serve as mediators of its
action. Lysosomal protease cathepsin D is one of them. After its activation by
ASMase derived ceramide, the mature form of cathepsin D is released in the
cytosol and triggers mitochondrial death pathway [54].
ASMase has an important role in pathogen infection and recovery.
ASMase knockout mice easily succumb to infections with P. aeruginosa, L
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monocytogenes, and alphaviruses [55, 56]. However, during bacterial or viral
infections the role of ASMase is most likely linked to membrane reorganization
and impact on internalization and vesicle fusion rather than modulation of
signaling pathways. ASMase deficient cells are incapable of P.aeruginosa
internalization and apoptosis, which are essential to clear the pathogen. The
mechanism underlying high susceptibility of ASMase knockout mice to L.
Monocytogenes revealed that a lack of ASMase activity leads to impaired phagolysosomal fusion, which is required for lysosomal degradation of the bacteria
[57]. The role of ASMase activity in viral infections is very diverse. It appears to
be important for the uptake of rhinoviruses as well as the infection and replication
of herpes virus [58]. Ng et al demonstrated that after infection with Sindbis virus
ASMase deficient cells produced more infectious virions compared to the control
cells [59].

8

9

Figure 1.1. Summary of the stimuli activating TNF producing cells and
subsequent biological effects initiated by TNF.

10

Figure 1.2. Metabolic pathways responsible for ceramide synthesis and
degradation. The names of relevant subcellular organelles are shown in bold.
Black solid arrows are used to depict metabolic conversions. Black dashed
arrows indicate protein-mediated or vesicular transfer. Abbreviations: ACDase,
Acid Ceramidase; ASMase, Acid Spjingomyelinase; Cer, ceramide; C-1-P,
ceramide-1-phosphate; dhCer, dihydroceramide; dhSph, dihydrosphingosine;
NSMase2,

neutral

sphingomyelinase

2;

SK,

sphingosine

kinase;

SM,

sphingomyelin; Sph, sphingosine; SMS, sphingomyelin synthase; SPPase,
sphingosine phosphate phosphatase; SPT, serine palmitoyltransferase; SSMase,
secretory sphingomyelinase

11

Figure 1.3. Agonists and signaling pathways for activation of Acid and
Secretory sphingomyelinases.

Copyright © Krasimira Rozenova 2009
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CHAPTER TWO

LPS-induced production of TNF by macrophages. In vivo and in vitro
models to study the role of ASMase in LPS signaling

A. Introduction

Macrophages play a pivotal role in the production and regulation of TNF
levels. TNF is one of the first pro-inflammatory cytokines secreted in response
to bacterial infection and appears to mediate the majority of the symptoms seen
in sepsis [60, 61]. The rate of TNF biosynthesis increases 1000 fold or more
following stimulation with LPS, which makes it one of the most potent inducers of
TNF production by macrophages [62].
LPS is a component of the outer membrane of gram-negative bacteria and
is indispensable for the integrity of the bacterial membrane. It has been
estimated that one bacterial cell contains approximately 3.5x106 LPS molecules,
which occupy three-quarters of the bacterial surface [63]. LPS consists of 3
components: lipid A, core oligosaccharide, and polysaccharide side chain (Ospecific chain). Lipid A is the active component recognized by the innate immune
system [64].
In the circulation, LPS is present in a complex with LPS binding protein
(LBP). The recognition of LPS at the cell surface is required for the initiation of
the transmembrane signal leading to cell activation, and involves at least 3
proteins: CD14, MD-2, and TLR4. CD14 can exist as a soluble molecule, but is
more often anchored to the plasma membrane by a glycosylphosphatidylinositol
anchor. It facilitates the transfer of LPS from LBP to a TLR4/MD-2 receptor
complex [65, 66]. MD-2 is an indispensable molecule in the LPS sensing
complex

and

physically

associates

with

the

signaling

receptor

TLR4.

Dimerization of the receptor initiates the signal transduction by the engagement
of cytosolic adaptor proteins. MyD88-dependent signaling cascade is wellstudied and depends on the phosphorylation and proteosome-mediated
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degradation of IRAK-1. This is crucial for the activation of downstream targets
such as MAP kinases and transcription factors including NF-B, AP-1, Ets, and
Elk-1 [67]. In vitro stimulation of macrophages with LPS results in a number of
changes in the transcriptional and translational machinery of the cell, which favor
the production and release of TNF. Transcription of the TNF gene leads to the
production of a single mRNA product. The control of TNF-gene expression is
mediated primarily by NF-B binding sites present within the TNF gene
promoter [68-71], although the requirement of raf-1/MEK-1/2/ERK1/2 has been
also suggested by number of studies [62, 72]. It has been found that treatment of
cells with ERK inhibitor PD-098059 reduced TNF mRNA expression in a dose
dependent manner and TNF secretion was completely abolished in the
presence of Ro 09-2210, a MEK inhibitor, which blocks not only activation of
ERK1/2, but also JNK and p38 [73]. Additional studies further supported the role
of p38 activation for TNF production [74] and also suggested that JNK might be
involved in the translational regulation of TNF [75]. Translational activation of
TNF is dependent on a conserved element found within the 3’ untranslated
regions [76]. Translation of mouse TNF mRNA produces the 26kD TNF
precursor, which has 233 amino acids and undergoes post-translational
glycosylation giving rise to several modified species which are susceptible to
treatment with glycosylase inhibitors and contribute to the smear like pattern
seen on a Western blot [77]. An additional form of sTNF with an estimated
molecular weight of 19kDa has been observed and was shown to contain
additional amino acids from the precursor protein as a result of different posttranslational processing [78]. Glycosylation of TNF has not been detected in
human samples and its physiological importance in mouse is currently unknown.
However, it was determined that it does not interfere with the biological activity of
this cytokine in vitro [78].
The TNF precursor contains a highly conserved sequence of 79 amino
acids at the N-terminus, which serves to anchor proTNF in the plasma
membrane. The precursor is a type II membrane protein with 18 amino acids
comprising the hydrophobic transmembrane region. The 26kD form is
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proteolitically cleaved by the TNF converting enzyme (TACE) to give a 17kD
active form. sTNF exists in solution as a homotrimer with a total molecular
weight of 52KD. This is the form that binds to the TNF receptors and exerts its
biological effects.
LPS also activates the secretory and lysosomal forms of Acid
sphingomyalinase, one of the major ceramide producing enzymes. Importantly,
accumulation of ceramide after LPS stimulation has been also reported and
coincides with the peak of ASMase activity. ASMase is proposed to mediate
many of the cellular effects of LPS, including the induction of apoptosis in
endothelial cells, hepatic necrosis, etc [53]. Although the effects of ceramide on
LPS-induced signaling molecules are various and often depend on the cell type,
ASMase derived ceramide appears to play an important role as a modulator of
LPS response. Whether ASMase affects TNF production is unclear, however
such effect is likely because ASMase is proposed to mediate the activation of
NF-B and JNK in response to other agonists.
In humans, a genetic deficiency of ASMase results in autosomal recessive
Niemann-Pick disease (NPD), which is further divided into type A and B based
on clinical and pathological findings. Mutations in the ASMase gene cause an
abnormal accumulation of sphingomyelin and in patients with the more severe
form of the disease (type A) this affects the function of visceral organs and brain,
and leads to lethality at early age. Fibroblasts from patients with NPDA are often
used to study the role of ASMase in various cellular responses.
A valuable tool to study the enzyme functions in vivo is the colony of ASMase
knockout mice, which lack both the lysosomal and secretory forms of ASMase
These mice also serve as source for a variety of cell types lacking ASMase
activity and represent an animal model for the human disease since at age of 4
months they develop the neurodegenerative phenotype seen in NPDA patients.
Acute inhibition of ASMase has been achieved by the tricyclic amines such as
desipramine and amitriptyline and is also frequently used in cell culture models.
These amphiphilic drugs displace the enzyme from lysosomal membranes,
making it vulnerable to proteolytic degradation [79].
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The major goal of the studies presented in this chapter is to develop an
experimental system in vivo and in vitro to study the regulation of TNF
production in response to LPS, as well as to decipher the role of ASMase and
ceramide in these regulatory mechanisms.

B. Materials and Methods

Materials

LPS (E. coli, Serotype 026:B6), Desipramine hydrochloride, and Brewer
thioglycollate broth were purchased from Sigma-Aldrich Co. (St. Luis, MO). The
enhanced chemifluorescent kit was from GE Healthcare (Piscataway, NJ).
Antibodies were from the following manufacturers: anti-phospho-ERK1/2, and
anti-IRAK-1 were from Santa Cruz Biotechnology (Santa Cruz, CA); anti-TNF
anti-cyclophilin A were from Cell signaling (Beverly, MA) anti--actin and alkaline
phosphatase conjugated secondary antibodies were from Sigma-Aldrich Co. (St.
Luis, MO). Trizol and Superscript IITM reverse transcriptase were from
Invitrogen (Carlsbad, CA). Random hexamers were from Roche (Indianapolis,
IN). Taq DNA polymerase was from New England Biolabs (Ipswich, MA).
RNeasy Mini Kit and siRNAs (scrambled and ASMase-specific) were from
Qiagen (Valencia, CA).

Animals

C57BL/6 mice were maintained in the AAALAC-approved animal facility of
the University of Kentucky Medical Center and placed on a standard NIH-31 diet,
with a 12-h light/dark cycle in microisolation. Mice were injected i.p. with LPS
(5.8mg/kg b.w.) or an equivalent volume of 150mM NaCl. Blood was collected by
cardiac puncture and serum was obtained in serum separator tubes.
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Cell cultures and treatment

RAW264.7 cells were maintained in DMEM supplemented with 100
units/ml penicillin/streptomycin (Gibco Laboratories, Grand Island, NY) and 10%
heat inactivated FBS. Cells were plated in 35mm dishes and used for
experiments at a density of approximately 2x106 cells/dish.
Two different ASMase-specific siRNAs (Quigen#SI00200753 and [80] )
were used for silencing of the endogenous ASMase expression. BLAST search
confirmed that the sequences were specific for the smpd1 gene. Cells were
plated in DMEM at density 0.7x106 cells/dish and transfections (160 pmol of
siRNA per dish) were performed 16 hours later using LipofectamineTM according
to the manufacturer’s instructions. Control plates were transfected with nonsilencing scrambled siRNA. Transfection efficiency was monitored after
transfection with Alexa Fluor555-labeled scrambled siRNA.
Treatments with LPS were done at 19 hours after plating. Where indicated, cells
were pretreated for 2 hours with 25M Desipramine.
Peritoneal macrophages were elicited with thioglycollate from 8 weeks old
asm+/+ mice. Cells were plated in DMEM, and supplemented with 2% heat
inactivated FBS on 6-well plates at a density of 2x106cells/well. Macrophages
were allowed to adhere for 3 hours in a 37C humidified 5% CO2 incubator and
non-adherent cells were removed by aspiration.
Human fibroblasts from healthy individuals and patients with NiemannPick Disease Type A were maintained in MEM supplemented with 15% FBS.
Cells were plated in 60mm dishes and used for experiments at density of
approximately 106 cells/dish. Cells and medium were used for Western blotting
48 hours following transfection.

SDS-PAGE and Western blotting of medium and cell lysates
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Conditioned medium was collected from wells, each containing 2x106
cells, cleared by centrifugation, and concentrated ten fold using Amicon Ultra
tubes with a cutoff of 10kD. Ten microliters from the concentrated medium were
subsequently used for Western blotting. Cells were lysed on ice for 30 min in a
buffer containing 1mM EDTA, 1% Triton X-100, 1mM Na2VO4, 1mM NaF, and a
protease inhibitor cocktail (1:200) in 10mM Tris-HCl, pH 7.4. Cell debris was
removed by centrifugation at 16,000xg for 10min at 4C. Proteins were resolved
by 10% SDS-PAGE, transferred to PVDF membranes and detected using the
antibodies described above. Protein-antibody interactions were visualized using
an ECF substrate and a Storm860 (Molecular Dynamics) Scanning Instrument,
and analyzed using Image Quant 5.0 software.

RNA isolation and cDNA synthesis

Total RNA was isolated with Trizol Reagent (RAW 264.7 cells) or RNeasy
Mini Kit (peritoneal macrophages) according to the manufacturer’s instructions.
cDNA was generated from total RNA using Superscript II reverse transcriptase
and random hexamers.

Reverse transcription (RT)-PCR

cDNA from RAW264.7 cells was used as a template for RT-PCR analysis
using primers specific for TNF (forward, 5’-tagccaggagggagaacaga-3’, reverse,
5’- cacttggtggtttgctacga-3’) or -actin (forward, 5’-tatggagaagatttggcacc-3’,
reverse, 5’-gtccagacgcaggatggcat-3’). PCR products were separated on 1.8%
agarose gel in the presence of ethidium bromide. The specific bands for TNF
(436bp) and -actin (300bp) were visualized under UV light.

Quantitative real-time PCR
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qRT-PCR was performed using TaqMan gene expression assays for
mouse TNF (Mm00443258_m1) and GAPDH control (Applied Biosystems,
Foster City, CA) according to the manufacturer’s instructions. Reactions were
performed in triplicates in 96 well plates on an ABI Prism 7700 Sequence
Detection System and analyzed with SDS 1.9.1 software (Applied Biosystems).
Levels of TNF mRNA were normalized to GAPDH mRNA.
ELISA

The levels of TNF, IL-1, and IL-6 were determined by ELISA in 50l
samples, according to the manufacturer’s protocol. The absorbance was
measured at 450nm on a Vmax kinetic microplate reader with Softmax pro
software (Molecular Devices). The sample values were calculated using a
standard curve (0 - 1,500 pg/ml) and expressed per 106 cells or per ml serum.

ASMase acitivity assay

RAW264.7 cells were incubated for 2 hours in the absence or presence of
25M desipramine. Cells were harvested and after centrifugation the pellet was
re-suspended in PBS. Cells were homogenized by sonication and 20g of total
protein was incubated in an assay mix (0.5M acetate buffer pH4.5, 3M NBDSM, 15mM NaF, 1mM -mercaptoethanol, protease inhibitors (1:200)) for 3h at
37C. The reaction was stopped by addition of 0.5ml methanol. Cell debris was
pelleted by centrifugation for 10 minutes at 16,000x g. The supernatants were
analyzed by high performance liquid chromatography (HPLC) on a reversephase column (Nova PAC, C18) using methanol: water: orthophosphoric acid
(850: 150: 0.150 by volume) as a mobile phase at a rate 2 of ml/min. NBDceramide formation was quantified after calibration using NBD-ceramide as an
external standard.
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Statistical analysis

Significant changes in multiple comparisons of two independent variables
(treatment and genotype) were determined by two-way ANOVA with Bonferoni
post-test. To test for differences among two or more independent groups
unpaired t-test and one-way ANOVA were also used. A P-value <0.05 was
considered significant. Data are reported as mean  s.e.m (or  s.d). The star
symbol indicates the significance of the main effect (treatment or genotype) and
a pound symbol indicates the significance of the interaction effect in two-way
ANOVA analysis.

C. Results

C.1. Studies in RAW264.7 cells

Characterization of LPS signaling in macrophage cell line RAW264.7

To test the response of RAW264.7 cells to LPS stimulation, the activation
of cell signaling molecules in the TLR4 proximity was assessed. Upon stimulation
of the receptor, the adaptor molecule IRAK-1 becomes phosphorylated and
degraded and the rate of its degradation has been linked to the extent of MAP
kinase activation [81]. Therefore, the degradation of IRAK-1 was first
investigated. RAW264.7 cells were treated with 10ng/ml LPS for various times
and the degradation of IRAK-1 was monitored by Western blotting. As
anticipated, the levels of IRAK-1 gradually decreased for up to 90 min following
stimulation (Fig. 2.2 A). Next, the activation of downstream targets JNK and ERK
was also tested by Western blotting using antibodies against the phosphorylated
forms of these MAP kinases. In untreated control cells pJNK and pERK were
almost undetectable, but transient phosphorylation of both kinases was
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demonstrated in response to LPS, with maximum response at 30-40 min after
stimulation followed by a decrease (Fig. 2.2 B, C). Dose dependent
phosphorylation of JNK and ERK to increasing concentrations of LPS revealed
that at 30 min, 5-10ng/ml of LPS was sufficient to induce maximum response
(Fig. 2.3 A, B). These data indicate that RAW 264.7 cells respond potently to
stimulation with LPS.

Production and release of TNF by LPS stimulated RAW264.7 cells

To understand the dynamics of TNF production and secretion by
RAW264.7, the levels of TNF mRNA were measured by RT-PCR, while the
levels of TNF in cell lysates and conditioned medium were measured by
Western blotting. LPS-induced production of TNF mRNA was detectable as
early as 1 hour after stimulation and was maintained for up to 6 hours (Fig. 2.4
A). At the protein level, the TNF detected in the cell lysates corresponded to the
26kD precursor form, while in the medium a band with a molecular weight of
17kD was found and represented the mature sTNF, which was additionally
confirmed with the positive control recombinant TNF (Fig. 2.4 B). The dynamics
of TNF production and cleavage was further followed. In RAW264.7 cells
proTNF was detected as early as 2 hours and remained elevated for at least 10
hours, although some decrease was observed after 6h (Fig. 2.4 C). The
appearance of sTNF in the medium followed closely the levels of proTNF in
the cells, showing a slight delay in secretion. sTNF was first detectable at 4
hours and continued to accumulate for at least 6 more hours (Fig. 2.4 D). In
agreement with previous studies, a 17kDa unmodified form of sTNF was
predominant in the medium, although bands with a higher molecular weight were
also detected (Fig. 2.4 D). It has been suggested that the majority of the proteins
in the “ladder” are N-glycosylated forms of the 17kD sTNF [77].

C.2. Studies in primary peritoneal macrophages
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Induction of TNF mRNA synthesis and sTNF secretion in primary
peritoneal macrophages after stimulation with LPS

Primary

peritoneal

macrophages

were

also

tested

as

a

more

physiologically relevant cell culture model to study TNF secretion in response to
LPS. First, peritoneal macrophages were stimulated with 10ng/ml LPS and the
levels of TNF mRNA were measured by quantitative real-time PCR. Similarly to
RAW264.7, in primary macrophages LPS induced robust synthesis of TNF
mRNA, which at its peak levels (4 hours) was more than a 100 fold higher
compared to the vehicle treated control (Fig. 2.5 A). This induction, however was
transient and at 6 hours post LPS a decrease in TNF mRNA abundance was
apparent.
The secretion of TNF by activated macrophages was monitored by
Western blotting. As expected, sTNF accumulated in the medium with a similar
kinetic as observed in RAW264.7 cells: it was detectable at 4 hours and
increased at the later time points (Fig. 2.5 C). Furthermore, there was neither
difference in the molecular size of the major 17kDa unmodified form nor in the
glycosylation pattern between both cell types. However proTNF in cell lysates
from peritoneal macrophages was almost undetectable even though the amount
of total protein which was loaded was the same as in RAW cells (Fig. 2.5 B).
These results may indicate that despite a strong activation of LPS signaling and
TNF synthesis in both cell types, there might be a significant difference in posttranslational processing of proTNF.

C.3. Studies in mice
Dynamics of cytokine production in response to LPS in vivo

To develop a model to study TNF production in vivo, mice were injected
with saline or sub-lethal dose of LPS (5.8mg/kg) and the serum levels of TNF,
IL-1, and IL-6 were measured by ELISA. The administration of LPS led to mild
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and temporary inflammatory reaction in the host. A slight elevation in body
temperature and lack of tonus were observed within a couple of hours. In all
animals, these symptoms disappeared after approximately 6 hours. Control
animals had undetectable levels of TNF and IL-1, but IL-6 ranged from 2 to
4ng/ml (Fig. 2.6 C, 0 time LPS). However, i.p. administration of LPS quickly
induced a sharp but transient increase in the circulating levels of all three
cytokines. Among them, the increase in TNF secretion was the most rapid and
dramatic, reaching 2.5ng/ml (more than 2000 fold increase over control animals)
1 hour after LPS injection (Fig. 2.6 A). The maximum levels of IL-1 and IL-6
were detected at 2h post stimulation (Fig. 2.6 B, C). These data are in agreement
with previously published results and underlines the significance of TNF as one
of the earliest and most potent pro-inflammatory cytokines secreted during
sepsis.

C.4. ASMase-deficient cells and animals as a model to study the role of
ASMase in the LPS-induced TNF synthesis

To study the role of ASMase and ASMase-derived ceramide in the
regulation of TNF production different in vivo and in vitro models were
developed.

C.4.1. Inhibition of ASMase in RAW264.7 cells

To generate ASMase deficiency in RAW264.7 cells, a pharmacological
inhibition of ASMase activity was first used. Desipramine is a cationic amphiphilic
drug, which accumulates in the acidic compartments of living cells, since it is
trapped as membrane-inpermeable form subsequent to its protonation in the
acidic environment. This tricyclic amine decreases the binding of ASMase to its
membrane-bound lipid substrate, which exposes the enzyme to lysosomal
proteases and make it susceptible to proteolytic degradation [79]. Desipramine is
widely used to inhibit ASMase activity, although some effects on acid ceramidase
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have been also reported [80]. Treatment with 25M desipramine was sufficient to
inhibit more than 90% of ASMase activity in RAW264.7 cells when it was applied
for 2 hours (Fig. 2.7 A). Importantly, the activity of Neutral sphingomyelinase
(NSMase) in the same cells was not influenced by desipramine (Fig. 2.7 B).
NSMase is the other signaling enzyme, which upon activation hydrolyzes
sphingomyelin to ceramide; therefore, this result suggests that desipramine
inhibits only the generation of ceramide by ASMase but not NSMase.
siRNA-mediated silencing was also tested as an alternative approach to
suppress ASMase activity in RAW264.7 cells. Using fluorescently labeled siRNA
(non-silencing siRNA-AlexaFluor555) the transfection conditions were first
optimized to ensure maximal transfection efficiency. More than 70% of the cells
contained siRNA based on the immunofluorescence (Fig. 2.8 A,B). Then, two
different ASMase-specific siRNAs were used to knockdown ASMase. However,
24 and 48 hours after transfection the activity of ASMase was not different
between the cells transfected with either of the silencing siRNAs and scrambled
siRNA. A maximum of 10% inhibition was achieved at 72 hours after trasfection
but it was still not significant compared to control cells (Fig. 2.8 C). Therefore,
inhibition by desipramine but not silencing of ASMase by siRNA was used in
further studies to inhibit ASMase in RAW264 cells.

C.4.2. Testing of ASMase-deficient fibroblasts, acquired from
Niemann-Pick Disease patients and control healthy individuals, as a model
to study the role of ASMase in TNF production in response to LPS

Niemann-Pick disease (NPD) belongs to lysosomal storage diseases and it is
characterized by a lack of ASMase activity. Mutations in the ASMase gene cause
an abnormal accumulation of sphingomyelin, and in patients with the more
severe form of the disease (type A) this affects the function of visceral organs
and brain, and leads to lethality at an early age. Fibroblasts from patients with
NPDA are often used to study the role of ASMase in various cellular responses.
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Therefore, we tested fibroblasts from individuals with NPDA and healthy
controls with intact ASMase activity as a model for deciphering the role of
ASMase in TNF production. After confirming the absence of ASMase activity in
firbroblasts from NPDA patients (Fig. 2.9 A), control fibroblasts were treated with
increasing concentrations of LPS and the levels of proTNF in cells and sTNF
in medium were monitored by Western blotting. However, TNF was not
detectable either in the cells or in the medium even after treatment with 1g/ml
LPS, which is a concentration 100 fold higher compared to that used for
treatment of macrophages (Fig. 2.9 B, C). Raw264.7 cells were used as a
positive control in these experiments. Thus, these results demonstrated that
fibroblasts were not an appropriate system to study TNF secretion.

C.4.3. ASMase-deficient mice and macrophages as a model to study
the role of ASMase in LPS-induced TNF production
Asm-/- mice are the animal model of the human genetic disease NPDA.
Therefore, asm-/- and litter-matched asm+/+ (Fig. 2.10) mice, as well as peritoneal
macrophages isolated from these mice, are a physiologically relevant model to
understand the role of ASMase in TNF production in response to LPS.

D. Discussion

The data presented in this chapter demonstrated that macrophages
responded rapidly and strongly to LPS stimulation since the maximum activation
of MAP kinases, ERK and JNK, was achieved 30-40 min following stimulation
and as little as 1ng/ml of LPS was able to induce their phosphorylation. As
discussed earlier the activation of MAPK has been strongly correlated with TNF
production. Consistent with these findings, LPS induced potent secretion of
TNF in both isolated peritoneal macrophages and the macrophage cell line,
RAW264.7. Importantly, the time course for detection of TNF in the medium as
well as the molecular weight of TNF were essentially the same for both cell
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types. Although the 17kD unmodified form was the most abundant, additional
bands with higher molecular weight were also detectable when substantial
amount of medium was used for Western blotting. This pattern of “protein ladder”
is consistent with previous studies demonstrating that the higher molecular bands
represent TNF glycosylated at different positions [77]. The physiological
significance of this modification is currently unknown. However it has been
shown that it does not influence the activity of sTNF [78].
RAW 264.7 cells and primary peritoneal macrophages appeared to be
similar in terms of sTNF secreted in the medium, however there was a striking
difference in the levels of proTNF detected in cell lysates. Despite equal
amounts of total protein used for Western blotting, proTNF was almost
undetectable in primary cells but abundant in RAW264.7 cells. These results
indicate that there might be cell specific differences in the post-translational
processing of proTNF by RAW 264.7 cells and peritoneal macrophages.
Differences were also apparent between LPS-induced TNF secretion in
vivo and in vitro, since the stimulation of TNF was much more rapid in vivo than
in vitro - systemic TNF peaked at 1 hour, while the earliest time point at which
TNF was detected in the medium was 4 hours. Additionally, the increase in
TNF levels was much more transient in vivo than in vitro; TNF in the serum
reached almost basal levels 6 hours after LPS administration, while in the
medium it was readily detectable for more than 10 hours. Although the exact
mechanisms for these differences are not precisely defined, there are several
plausible explanations: Since the levels of TNF mRNA started to decline after 4
hours, the accumulation of TNF in the medium is most likely due to the lack of
effective clearance mechanisms in vitro. In the circulation TNF is rapidly cleared
by the kidneys and liver, with estimated half-life of 6 to 20 min [82]. The delayed
secretion of TNF in vitro also can be due to the absence of factors, such as
LBP, which have co-stimulatory effect in vivo, and facilitate the binding of LPS to
the receptor and initiation of signal transduction. This possibility is further
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supported by findings reported by Wollenberg et al. [83], that not only sTNF but
also TNF mRNA reaches its peak levels much faster in vivo than in vitro.
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Figure 2.1. TNF synthesis and secretion in response to LPS stimulation.
The binding of LPS to the TLR4 signaling receptor induces phosphorylation and
degradation of the adaptor molecule IRAK-1, which is essential for activation of
downstream targets including MAP kinases. Phosphorylation of JNK, ERK, and
p38, as well as degradation of I-B, ultimately lead to nuclear translocation of
transcription factors such as NF-B, Elk-1, Egr-1, ATF-3, which are implicated in
the initiation of TNF gene transcription. LPS stimulation increases the stability of
TNF mRNA, which is translated into 26kD TNF precursor (proTNF). proTNF
is transferred to the plasma membrane, where it is cleaved by TACE to produce
the 17kD soluble biologically active TNF (sTNF).
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Figure 2.2. Time course of IRAK-1 degradation and phosphorylation of ERK
and JNK in RAW264.7 cells stimulated with LPS.

RAW264.7 cells were

treated with LPS (10ng/ml) for the indicated time. The rate of IRAK-1 degradation
(A, B) and phosphorylation of JNK (C, D) and ERK (E, F) was detected by
Western blotting using specific antibodies. Cyclophilin A was used to ensure
equal protein loading. Representative image is shown and the quantification of
the band intensity for IRAK-1, pJNK, and pERK is presented normalized to the
levels of cyclophilin A in the same sample (B, C, D)
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Figure 2.3. Dose dependent phosphorylation of ERK and JNK after LPS
treatment.

RAW264.7

cells

were

treated

for

30min

with

increasing

concentrations of LPS. Phosphorylation of JNK (A, B) and ERK (C, D) was
determined by Western blotting using antibodies specific for the phosphorylated
forms of JNK and ERK. Cyclophilin A was used to control for uniform loading.
Representative image is shown and the quantification of the band intensity for
pJNK, and pERK is presented after normalization to the levels of cyclophilin A in
the same sample (B, D).
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RAW264.7 cells

Figure 2.4. TNF mRNA levels and post-translational processing of TNF
precursor in RAW264.7 cells. RAW264.7 cells were treated with LPS (10ng/ml)
for the indicated times. A. TNF mRNA levels. Total RNA was isolated by Trizol
reagent and the levels of TNF mRNA were determined by RT-PCR. The
expression level of -actin mRNA was used to control for uniform loading (A). BD. TNF processing. The kinetics of 26kD proTNF processing to 17kD sTNF
was determined by Western blotting. Recombinant human TNF was used as a
positive control for sTNF (B). Time course of proTNF production in cell lysates
(C) and its cleavage to sTNF measured in the medium (D).
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Primary peritoneal macrophages

Figure 2.5. TNF mRNA levels and post-translational processing of TNF in
primary peritoneal macrophages. Peritoneal macrophages were isolated from
C57BL/6 mice and treated with LPS (10ng/ml) for the indicated times. A. TNF
mRNA expression. The levels of TNF mRNA in each sample were measured
in triplicates by quantitative real-time PCR and normalized to GAPDH levels in
the same sample. The results from two independent experiments are shown and
expressed as percent of the maximum response (A). B and C. TNF
processing. The levels of proTNF in cell lysates (B) and sTNF in the medium
(C) were determined by Western Blotting. -actin levels were used to control for
uniform loading.
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Figure 2.6. Cytokine levels in LPS-injected C57BL/6 mice.
C57BL/6 mice were injected i.p. with LPS (5.8mg/kg body weight) or saline.
Serum was collected at the indicated times and the levels of TNF (A), IL-1 (B),
and IL-6 (C) were measured by ELISA. Only the data for LPS-injected animals
are shown. The levels of the cytokines in saline-injected animals were below the
detection levels for TNF and IL-1 and were around 2ng/ml for IL-6 (C). The
combined data from three independent experiments are shown as group average
 s.e.m. The significance of the LPS treatment effect (**, P<0.01, *, P<0.05) is
based on one-way ANOVA.
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Figure 2.7. Effect of desipramine on ASMase and NSMase activity in
RAW264. 7 cells. RAW264.7 cells were treated with desipramine (25M) for 2
hours. ASMase (A) and NSMase (B) activities were measured in cell lysates by
using NBD-sphingomyelin as a substrate and HPLC method. Statistical
significance of desipramine effect is shown (***<0.001) based on unpaired
student t-test.
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Figure 2.8. ASMase silencing by siRNA in RAW264.7 cells. RAW264.7 cells
were transfected with either scrambled or ASMase specific siRNA. Transfection
efficiency at 6 hours is shown after using scrambled siRNA labeled with Alexa
Fluor 555 and fluorescent microscopy (A). Transmitted light images of RAW264.7
cells (B). ASMase activity was measured in cell lysates from RAW264.7 cells
transfected for 24, 48, or 72 hours with control or ASMase specific siRNA. Two
different ASMase specific siRNAs were used designated as ASMase siRNA 1
and ASMase siRNA 2 (C).
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Figure 2.9. Characterization of LPS response in human fibroblasts. A.
ASMase activity. ASMase activity in fibroblasts from healthy individuals or
patients with type A Niemann-Pick Disease measured by the HPLC method (A).
B and C. TNF levels. Human skin fibroblasts from healthy individuals were
treated for 4 hours with increasing concentrations of LPS and the levels of
proTNF in cell lysates (B) and sTNF in medium were determined by Western
blotting. Cell lysate and medium from LPS stimulated RAW264.7 cells were used
as a positive control.
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Figure 2.10. ASMase-deficient mice - an in vivo model to study the role of
ASMase in TNF secretion. The offspring of heterozygous (asm+/-) breeding
pairs were genotyped after weaning by using PCR of tail DNA. Around 25% of
the mice were asm-/- and had single PCR product of 550bp. Litter-matched asm+/+
controls were also around 25% of the offspring and had single PCR product of
300bp. In the heterozygous mice two bands corresponding to 550bp and 300bp
were detectable.

Copyright © Krasimira Rozenova 2009
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CHAPTER THREE

Role of ASMase and ceramide in the transcriptional regulation of TNF
synthesis in response to LPS

A. Introduction

LPS is one of the most potent agonists that activates mononuclear cells to
produce TNF. The recognition of LPS by macrophages is mediated by LBP,
which binds to the lipid A moiety [84] and greatly increases host sensitivity to
LPS [85]. LBP-LPS forms a ternary complex with CD14, which enables LPS to be
transferred to the signal transducing receptor complex. CD14 exists in two forms:
a soluble CD14, which is found in the plasma; and membrane-bound CD14,
which

is

attached

to

the

surface

of

myeloid

cells

via

a

glycosylphosphatidylinositol anchor. The LPS-specific receptor complex is
composed of Toll-like receptor-4 (TLR4) and MD-2. MD-2 is secreted
glycoprotein and acts as an extracellular adaptor protein in the activation of
TLR4. MD-2 is important for ligand recognition by TLR4 and is essential for LPS
signaling to occur. Mice lacking MD-2 are unresponsive to LPS [86]. TLR4 is the
first-discovered mammalian homologue of Drosophila Toll. TLR4 works
downstream of CD14 and is responsible for delivering an LPS signal.
Homodimerization of TLR4 recruits to the receptor complex adaptor proteins Mal
and MyD88, which, analogously to the IL-1 signaling, associate with IRAK-1
causing its phosphorylation. Phosphorylation of IRAK-1 is followed by its
ubiquitination and proteosome-mediated degradation, which determines the
magnitude of TLR response. For example, inhibition of IRAK-1 degradation in
macrophages by inhibitors of ubiquitin ligases has been found to potentiate the
inflammatory response, as judged by a more potent induction of JNK [87]. In turn,
decreased stability of IRAK-1 underlies the decreased response to a second
dose of LPS and is the cause of endotoxin tolerance [88].
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Hyperphosphorylation of IRAK-1 is also important for dissociation from the
receptor complex and association of IRAK with TRAF6, which is critical for the
activation of MAPK kinase TAK-1. TAK-1 acts as a common activator of NF-B
as well as of p38 and JNK. The activation of MEK/ERK1/2 pathway in response
to LPS appears to be Raf-1 dependent.
Most of the above mentioned signaling molecules have been shown to be
essential for TNF production and are implicated in various mechanisms of its
regulation. For example, stimulation of LBP production by LPS [89] has been
linked to an increase in TNF mRNA synthesis and stability [90]. The
requirement of CD14 for TNF synthesis was reinforced by the inhibition of TNF
production in the presence of blocking antibodies to CD14 [91]. Additionally, a
number of studies unequivocally demonstrated the importance of MAPK and NFB for LPS induced TNF production. For example, dominant-negative forms of
both Rac and c-Raf inhibited LPS induction of TNF promoter in RAW264.7 cells
[62]. It has also been found that treatment of cells with ERK inhibitor, PD-098059,
reduced TNF mRNA expression in a dose dependent manner; and TNF
secretion was completely abolished in the presence of Ro 09-2210, a MEK
inhibitor which blocks the activation of not only ERK1/2, but also JNK and p38
[73]. Additional studies further supported the role of p38 activation for TNF
production [74], and also suggested that JNK and p38 might be involved in the
translational regulation of TNF [75, 92, 93].
The enhancement of transcription initiation, release of the transcript
elongation block, and transcript stabilization contribute to the accumulation of
TNF mRNA in stimulated macrophages [94, 95]. Transcription factors such as
c-Jun, ATF-2, Egr-1, and Elk-1 [96], which are downstream targets of MAPK
have been shown to be essential for the initiation of transcription and RNA
synthesis. Many of the above mentioned factors bind to the proximal promoter
region, which plays an important functional role in the transcriptional regulation of
mouse TNF [97]. Chromatin immunoprecipitation revealed that ATF-2, c-Jun,
Elk-1, and Ets-1 bind to this region in J774 cells [98]. 5’ distal NF-B sites are
also important for maximum functional activity of mouse TNF gene [68, 97, 99].
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Finally, a mutation in the Egr-1 site in the TNF promoter significantly reduced
the level of LPS induction [67]. Once transcribed, TNF mRNA is stabilized after
LPS stimulation. Cis-acting elements in the TNF 3’-untranslated region are
sufficient for LPS-induced activation of TNF translation [76, 100]. All three MAP
kinases, ERK, JNK and p38 have been implicated in the regulation of TNF
mRNA stability [75, 101, 102].
The generation of ceramide in response to various stimuli has been linked
to both up-regulation and down-regulation of NF-B and MAPK activity in
different cell types. In IL-1 stimulated primary hepatocytes, ceramide produced
by NSMase led to an increase in JNK phosphorylation [81]. Activation of JNK by
ASMase-derived ceramide has also been reported after stimulation with UV light
[103], and after infection with Pseudomonas aeruginosa [104]. However,
ceramide generated after infection with protozoan parasite Leishmania donovani
inhibited ERK phosphorylation [105] and suppressed AP-1 and NF-B activation
[106]. Cell permeable C2-ceramide was shown to stimulate ERK activation, which
appeared to be important for smooth muscle contraction [107]. However, in RBL2H3 cells C2-ceramide suppressed phosphorylation of ERK and p38 [108].
Finally, ceramide stimulated p38 phosphorylation in HL-60 cells [109] but it was
linked to p38 dephosphorylation in PMA stimulated human breast cancer cells
[110].
Modulation of MAPK and NF-B activity, which are essential for TNF
transcriptional and translational regulation by ceramide, suggests that it might
play a role in TNF production. The effects of ceramide, however, appear to
depend on the stimulus, cell type, and pathway for its generation. Therefore, this
chapter investigated the role of ASMase-derived ceramide in LPS-induced
transcriptional regulation of TNF production.

B. Materials and Methods

Materials
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Bacterial sphingomyelinase (S. Aureus) was purchased from SigmaAldrich Co. (St. Luis, MO). C2-ceramide was from Avanti Polar Lipids (Alabaster,
AL).

Animals
A colony of ASMase knockout (asm-/-) mice maintained in C57BL/6
background were propagated using heterozygous breeding pairs and genotyped
by PCR of tail DNA. The mice received food and water ad libitum and were
housed in AAALAC-approved animal facility of the University of Kentucky
Medical Center. Litter-matched wild-type (asm+/+) and asm-/- mice were used for
experiments.

SDS-PAGE and Western blotting

Please refer to Chapter Two, Section B.

RNA isolation, Reverse transcription (RT)-PCR, and Quantitative real-time
PCR analysis

Please refer to Chapter Two, Section B.

ELISA
The levels of TNF in the medium from asm+/+ and asm-/- miacrophages
were determined by ELISA as described in Chapter one, Section B.
Statistical analysis

Please refer to Chapter Two, Section B.

41

C. Results

Genotype-specific differences in the level of TNF secreted by
macrophages stimulated with LPS

To test whether ASMase deficiency affected the production of TNF,
peritoneal macrophages were isolated from asm+/+ and asm-/- animals and
stimulated with LPS. The release of TNF in the medium was monitored by
ELISA. As anticipated, treatment with LPS induced TNF secretion, which
reached maximum at 4 hours after stimulation. However, TNF levels were up to
2 fold higher in asm-/- macrophages as compared to asm+/+ cells (Fig. 3.1 A),
although the difference tended to decrease at later time points (6 hours).
Furthermore, the effect of ASMase seems to be specific for TNF secretion,
since the levels of IL-1 were not significantly different between asm+/+ and asm-/macrophages (data not shown). ASMase deficient macrophages lack one of the
major enzymes responsible for the generation of ceramide, therefore to
demonstrate a direct link between ceramide and sTNF levels, asm-/- were
treated with cell permeable C2-ceramide and TNF levels were measured in the
medium. The addition of short-chain ceramide to asm-/- macrophages inhibited
sTNF secretion in a dose dependent manner (Fig. 3.1 B). Together, these
results indicate that ASMase and ceramide may regulate specific step(s) in TNF
production.

Effects of ASMase on TNF levels are not mediated by PGE2 or IL-6

The secretion of TNF by LPS-activated macrophages can be modulated
by a variety of pro- and anti-inflammatory mediators induced by LPS or TNF
itself. Therefore, it is important to understand whether ASMase directly affects
LPS-induced TNF production, or if it acts through secondary mechanisms.
Since PGE2 is one of the well-known negative regulators of TNF secretion, its
levels were measured in medium from asm+/+ and asm-/- macrophages. PGE2
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secretion was induced after LPS stimulation and gradually increased for at least
up to 8 hours. However asm-/- and control cells released similar levels of PGE2 at
all time points tested, suggesting that the differences in TNF secretion are not
attributable to a defect in PGE2 production (Fig. 3.2 A). Similarly, the
simultaneous treatment with IL-6, which can also suppress TNF synthesis, had
no effect on the genotype-related differences (Fig. 3.2 B).

ASMase deficiency has no effect on MAP kinase activation and TNF
mRNA production in peritoneal macrophages

To determine whether the observed differences in TNF secretion are
related to differences in the LPS signaling pathway at the plasma membrane, the
activation pattern of proteins proximal to the LPS receptor was first examined.
However, the IRAK-1 degradation rate was not different between genotypes (Fig.
3.3 A, B). Similarly, the pattern of ERK phosphorylation was not affected by the
lack of ASMase activity (Fig. 3.3 C, D). Finally, the magnitude and time course of
LPS-induced TNF mRNA production was the same in both genotypes (Fig. 3.3
E). These results are in agreement and extend previous studies that examined
the activation of MAP kinase pathway in macrophages from asm-/- and asm+/+
mice, and found no differences in the ability of TNF and LPS to induce
activation of ERK, JNK, p38 and NF-B [111].

Inhibition of ASMase by desipramine affects neither LPS-induced
phosphorylation of ERK and JNK nor TNF mRNA synthesis

The effect of ASMase on transcriptional regulation of TNF was also
tested in RAW264.7 cells, where acute inhibition of ASMase was achieved after
treatment with desipramine. Although desipramine suppressed ASMase activity
by more than 90% (See chapter two, Fig. 2.5 A), which was consistent with the
results from primary macrophages, the extent of MAP kinase phosphoryaltion
and induction of TNF mRNA synthesis were similar among treatments and were
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not influenced by ASMase deficiency (Fig. 3.4 A, B, C, D). Furthermore, the
treatment

of

RAW264.7

cells

with

either

C2-ceramide

or

bacterial

sphingomyelinase, both of which increased ceramide levels, did not have any
effect on TNF mRNA levels (Fig. 3.4 E). Altogether these results suggest that
ASMase and ceramide do not affect transcriptional regulation of TNF
production.

D. Discussion

The activation of ASMase by LPS followed by the generation of ceramide
have been previously reported and suggested to be important for the initiation of
signal transduction and regulation of the activity of signaling molecules such as
MAPK.

The results presented in this chapter demonstrated that ASMase is

involved in the regulation of TNF production following LPS stimulation, and the
lack of ASMase activity was linked to increased levels of sTNF, suggesting that
it plays a role of negative regulator of TNF production. Additional treatments
confirmed such a conclusion, demonstrating that exogenous ceramide is
sufficient to decrease sTNF in the medium. ASMase and ceramide appear to
influence directly LPS-induced TNF production, rather than working via
secondary mechanisms. However, the activation of ERK and JNK as well as the
levels of TNF mRNA were not influenced by ASMase deficiency in neither
primary macrophages nor RAW 264.7 cells, indicating that ASMase and
ceramide most likely affect step(s) of TNF production downstream of TNF
mRNA synthesis.
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Figure 3.1. Effect of ASMase and ceramide on TNF production in primary
macrophages. TNF levels measured by ELISA in medium of peritoneal
macrophages from asm+/+ (filled symbols) or asm-/- (open symbols). Cells treated
with LPS (100ng/ml, circles) or PBS (triangles) for the indicated times.
Representative results of three independent experiments are shown (A).

Cells

treated with LPS (10 ng/ml) for 4 hours in the presence of the indicated
concentrations of C2-ceramide or vehicle control (0.1% ethanol). Results
combined from two independent experiments are shown (B). Data are presented
as mean ± s.e.m. Statistical significance of the main effect (***, P<0.001) and the
interaction effect (###, P<0.001; #, P<0.05) are shown based on two-way
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ANOVA. The statistical significance of ceramide effects was calculated by oneway ANOVA (*, P<0.05).
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Figure 3.2. Role of ASMase deficiency on PGE2 production and IL-6 effects
on TNF secretion. Peritoneal macrophages from asm+/+ (filled bars) or asm-/(open bars) were treated with LPS (10ng/ml) for the indicated time. The levels of
PGE2 in cell-free conditioned medium were determined by ELISA and the results
were normalized to the cyclophilin A measured in the cells (A). Peritoneal
macrophages from asm+/+ or asm-/- were treated for 4 hours with LPS (10ng/ml)
in the absence or presence of IL-6 (20ng/ml). The levels of TNF (ng/ml) in the
medium were measured by ELISA.
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Figure 3.3. Stimulation of IRAK-1, ERK, and TNF mRNA in asm+/+ and asm/-

macrophages. Peritoneal macrophages from asm+/+ (filled bars) and asm-/-

(open bars) mice were treated with LPS (10ng/ml) for the indicated times. A-D.
Activation of IRAK-1 (A, C) and ERK1/2 (B, D). Analyses were done using
Western blotting and antibodies against IRAK-1 and phosphorylated ERK. Data
are representative of three independent experiments. -Actin levels were used
to control for uniform loading. (E) Stimulation of TNF mRNA. mRNA levels
were determined by real-time PCR. GAPDH mRNA level was used for
normalization.

Data are presented as mean ± s.e.m. of three independent

experiments. Statistical significance of the treatment effect is shown (***,
P<0.001) based on two-way ANOVA.
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Figure 3.4. Phosphorylation of ERK and JNK, and production of TNF
mRNA in LPS stimulated ASMase deficient and control RAW264.7 cells. AD. Effect of ASMase deficiency on the LPS-induced activation of ERK and
JNK. RAW264.7 pre-treated with desipramine (25M) to inhibit ASMase activity
and control cells were stimulated with LPS (10ng/ml) for 60 min. Phosphorylation
pattern of ERK (A) and JNK (C) after LPS stimulation was determined by
Western blotting using antibodies specific for the phosphorylated forms of these
MAP kinases. Quantification of pERK and pJNK band intensity is shown after
normalization to the cyclophilin A (B,D), used as a control for equal protein
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loading. E. Effect of ASMase deficiency and exogenous ceramide on TNF
mRNA production in RAW264.7 cells. RAW264.7 cells were treated for 2 hours
with LPS (10ng/ml) alone or in the presence of either desipramine (25M), C2ceramide (60M), or bacterial sphingomyelinase (0.1units/ml). The steady-state
levels of TNF mRNA were determined by RT-PCR.

Copyright © Krasimira Rozenova 2009

50

CHAPTER FOUR

Role of ASMase and ceramide in the post-translational regulation of TNF
synthesis in response to LPS

A. Introduction

The concept of post-translational regulation of TNF secretion in response
to LPS has been proposed more than 20 years ago [112]. However, the
mechanisms which regulate the rates of trafficking, processing, and release of
TNF (Fig. 4.1) remain mostly unknown.
In mice, TNF mRNA is translated into a 26kD precursor most of which is
associated with the Golgi complex [113]. Part of the newly synthesized protein is
immediately N-glycosylated [77]. proTNF residing in Golgi is selected as a
cargo for the golgin p230-positive vesicles [114] which fuse with rab11 recycling
endosomes en route to the plasma membrane [115].

The precursor is not

delivered randomly to the cell surface but it is highly concentrated in the
phagocytic cups [116] where it is integrated as a type II membrane protein. The
proteolytic cleavage of proTNF to the biologically active 17kD sTNF is
inhibited by cholesterol depletion and hydroxymate inhibitors, suggesting that it
takes place in cholesterol-rich membrane domains and the enzyme responsible
for proTNF shedding is a metalloprotease [116-118]. Indeed, it was confirmed
that at the membrane, proTNF ectodomain is cleaved by TACE, which is a
member of the ADAM (A Disintegrin And Metalloproteinase) family of proteases
[119]. In addition to TNF, TACE also processes the two TNF receptors (p55
and p75), transforming growth factor alpha (TGF), L-selectin, and other
secretory proteins.
Recent studies on TNF processing revealed that TACE activity might be
a rate-limiting step in TNF secretion [120]. For example, it was reported that a
substantial portion of proTNF that was not cleaved by TACE was rapidly
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internalized and either degraded in the lysosomes or recycled back to the plasma
membrane [121, 122].
TACE mRNA is expressed in most tissues and gives rise to an inactive
zymogen. Removal of the autoinhibitory prodomain occurs in a late Golgi
compartment, most likely by the action of furin or a related protease [123]. Only
processed TACE appears on the cell surface [124]. The stimulation of cells with
various agents can increase the rate of shedding. However, the mechanisms
underlying the regulation of TACE activity remain poorly understood. A role of the
cytoplasmic domain was suggested in response to intracellular signaling events
such as MAP kinase activation [125]. In favor of this is the finding that the
cytoplasmic domain is phosphorylated in response to shedding activators [126].
Nevertheless, TACE constructs lacking the entire cytoplasmic domain are fully
functional in shedding [127], indicating that other mechanisms must be also
involved. Another important question is what determines substrate selectivity of
the enzyme. Since the sequences cleaved in various substrates are highly
variable it was proposed that the distance between the membrane domain and
the cleavage site is important. However, interactions distal to the cleavage site
also appear to be required [127]. Finally, there is evidence to suggest that spatial
segregation or proximity of enzyme and substrate within the plasma membrane
may control some shedding activity.
At the plasma membrane, TACE activity appears to depend upon
compartmentalization of the protein in the ordered lipid domains. It is
controversial, however, whether localization in the ordered lipid rafts is linked to
stimulation or to inhibition of activity. It is also not known whether these observed
changes reflect differences in the co-localization of TACE and its substrates, or a
conformational change and catalytic activation of the enzyme.
Lipid rafts are loosely defined as domains on the plasma membrane that
are enriched in sphingomyelin and cholesterol. They constitute a unique liquid
ordered environment that includes or excludes specific subsets of proteins and
lipids. Sphingomyelin and cholesterol have a unique relationship in mammalian
cells that involves physical and metabolic interactions. First and foremost, the
presence of cis-, but not trans- double bond in the sphingoid moiety of
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sphingomyelin makes the molecule “flat”. This allows for close hydrophobic
interaction between sphingomyelin and cholesterol, evident by their ability to
aggregate in domains that exclude other lipids. Furthermore, the importance of a
hydrogen bond formed between the amide nitrogen of sphingomyelin and the
oxygen atom in the cholesterol hydroxyl group has also been suggested as a
structural basis for sphingomyelin:cholesterol complex formation [128, 129].
Translocation of ASMase to the plasma membrane leads to hydrolysis of
sphingomyelin and generation of ceramide, followed by exclusion of cholesterol
from the rafts and formation of large ceramide-enriched macrodomain platforms
[130].
Interestingly, the two lipids, sphingomyelin and cholesterol, affect each
other’s metabolism. Lowering of the content of sphingomyelin at the plasma
membrane dramatically alters the cholesterol distribution by mobilizing plasma
membrane cholesterol for esterification [43, 131], by decreasing sterol
biosynthesis [43, 132], and by activating the synthesis of steroid hormones in
steroidogenic cells [133]. The addition of cholesterol to cultured fibroblasts
inhibits their ASMase activity. Conversely, the loss of ASMase activity leads to
accumulation not only of sphingomyelin but also cholesterol [134], indicating that
there is a regulatory mechanism which maintains a fixed ratio of sphingomyelin to
cholesterol. Furthermore, the addition of bSMase that hydrolyses the SM at the
plasma membrane, stimulates cholesterol translocation from the plasma
membrane to the endoplasmic reticulum where it suppresses cholesterol
synthesis by inhibiting HMG-CoA reductase [135].
Overall, it is fairly well established that sphingomyelin and cholesterol
levels at the plasma membrane are coordinately regulated and affect signaling
events by re-organizing the signaling domains, e.g. lipid rafts. This may have
interesting implications for the regulation of TACE activity, since it has already
been suggested that sequestration of TACE in the sphingomyelin:cholesterol
rafts is rate-limiting for its activity [120].
Recent studies in mice have linked ASMase deficiency to increased
susceptibility to viral and bacterial infections [55, 56]. ASMase-deficient
macrophages exhibit a slow rate of elimination of pathogens like L.
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monocytogenes, alphavirus Sindbis and P. aeruginosa, caused by a protracted
phago-lysosomal fusion and membrane budding. A defect in the rab4 recycling
pathway has been identified in asm-/- fibroblasts isolated from patients with
Niemann-Pick Disease type A [136]. Together these studies suggest that in
addition to a role in signaling, ASMase might be involved in the regulation of
membrane fusion by regulating membrane fluidity and/or curvature.

B. Materials and Methods

Materials

Ammonium chloride was purchased from Sigma-Aldrich Co. (St. Louis,
MO).

Fluorogenic

Peptide

Substrate

III

and

anti-TNF

used

for

immunofluorescence came from R&D Systems (Minneapolis, MN). TAPI-1 (N(R)-[2-(Hydroxyaminocarbonyl)

methyl]-4-methylpentanoyl-L-naphtyl-alanyl-L-

alanine, 2-aminoethyl amide; TNF Protease Inhibitor-1) was from Calbiochem
(La Jolla, Ca). D-erythro-sphingosine was from Avanti Polar Lipids (Alabaster,
AL). Anti-EEA1 and anti-TACE antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA).

Animals
Litter-matched asm+/+ and asm-/- mice were maintained as described
earlier (Chapter three, Section B) and used for experiments.
SDS-PAGE and Western blotting

Please refer to Chapter Two, Section B for details in performing SDSPAGE and Western blotting.

ELISA
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The levels of TNF in the medium from asm+/+ and asm-/- miacrophages
were determined by ELISA as described in Chapter one, Section B.

TACE activity assay

Macrophages were resuspended in 500l detergent free 25mM Tris (pH
8.0) and homogenized by passing through a 26G needle several times. A total of
5-10g protein was incubated with 10M fluorogenic substrate III (Mca-P-L-A-QA-V-Dpa-R-S-S-S-R-NH2) in 25mM Tris, pH 8.0 (100l final volume). The
fluorescence was analyzed with excitation at 320nm and emission at 405nm.

Indirect Immunofluorescence
Cells were cultured on coverslips and treated as indicated. Fixation was
performed for 5 min in cold methanol (permeabilized cells) or for 30 min in 3%
formaldehyde (non-permeabilized cells). After blocking the non-specific binding
with appropriate serum (2%), the proteins of interest were labeled with anti-TACE
(1:50), anti-TNF (1:50) or anti-EEA1 (1:100) polyclonal antibodies. The immune
complexes were visualized with FITC-conjugated goat anti-rabbit IgG or TRITCconjugated bovine anti-goat IgG. In the co-localization studies, the primary
antibodies were added sequentially.

Statistical analysis

Please refer to Chapter Two, Section B.

C. Results

Kinetics of post-translational processing of TNF in primary macrophages
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To study the post-translational processing of TNF, the conversion of
proTNF to sTNF was monitored by Western blotting in primary macrophages
and RAW264.7 cells. As anticipated, neither proTNF nor sTNF forms were
detected in non-stimulated peritoneal macrophages from both genotypes (Fig.4.2
A, and B). Substantial accumulation of sTNF in the medium of LPS-treated
macrophages was noticeable at 6 hours after stimulation and continued for at
least 20 hours. The amounts of sTNF were higher in asm-/- than in asm+/+ cells,
which is in excellent agreement with the differences seen by ELISA. Surprisingly,
we were not able to detect any proTNF in the cellular lysates (Fig. 4.2A), which
is indicative that the steady-state levels of proTNF were very low. However, cotreatment with ammonium chloride, which blocks the activity of many lysosomal
hydrolyses led to very substantial accumulation of the precursor protein inside
the cells (Fig. 4.2 D), while having no effect on the levels of sTNF in the
medium (Fig. 4.2 E). These results are in good agreement with earlier
observations by other groups [122], indicating that proTNF that is not processed
by TACE is internalized and degraded in the lysosomes. Our study further
suggests that at least half of the newly produced proTNF undergoes such
degradation, based on calculations of the volumes that were loaded. Together,
these observations support the conclusion that in peritoneal macrophages the
activity of TACE is the rate-limiting factor in TNF processing and that at least in
primary macrophages, the lysosomal proteolysis of non-processed TNF is very
substantial and rapid.
Similar studies were also conducted in the macrophage cell line,
RAW264.7. As discussed in chapter 2, LPS treatment induced TNF production,
which was readily detected in the medium as well as in the cells. In contrast to
peritoneal macrophages the levels of proTNF in the cells were substantial.
Importantly, inhibition of ASMase activity by desipramine had only a slight effect
on proTNF and sTNF (Fig. 4.3 A, B, C). Furthermore, unlike primary
macrophages, the addition of ammonium chloride to RAW 264.7 cells to block
lysosomal proteolysis of TNF, did not influence the levels of proTNF detected
in cell lysates (Fig. 4.3 E). Together, these results indicate that there is a
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significant difference between primary peritoneal macrophages and RAW264. 7
cells in the post-translational regulation of TNF production. Apparently, in
RAW264.7 cells proTNF did not undergo efficient lysosomal proteolysis and its
levels were not affected by inhibition of lysosomal proteases. Because of these
differences between primary cells and the cell line, the latter was not used any
further.
Asm-/- macrophages have higher activity of TACE, which is inhibited by an
increase in ceramide content of the cells

To test directly whether increased TNF production in asm-/- was caused
by higher activity of TACE, the latter was measured using fluorogenic substrate
containing the TNF cleavage site. After identifying the range of linearity for the
in vitro assay (Fig. 4.4A, and B), the TACE activity was measured in detergentfree lysates from asm+/+ and asm-/- cells. Both, LPS- and control-treated
macrophages isolated from asm-/- mice exhibited 2 to 3 fold higher activity as
compared to their respective counterparts isolated from the asm+/+ mice. These
differences suggest that ASMase-derived ceramide might be a negative regulator
of TACE (Fig. 4.4C, and D).
To test this, the levels of cellular ceramide were elevated by the addition
of bacterial sphingomyelinase or cell-permeable ceramide analogue, C2ceramide, to the cultured cells. Both treatments inhibited TACE activity but
ceramide-mediated inhibition was more than 80% (Fig. 4.4E, and F). To test
whether ceramide has a direct effect on TACE activity, it was added directly to
the assay mixture. No inhibitory effect, however, was observed (Fig. 4.5.A). One
possible explanation for the differences in ceramide capacity to inhibit TACE in
cells but not in vitro was that in cells ceramide was metabolized. To test this, two
ceramide metabolites, sphingosine and dihydroceramide, were used. However,
these treatments also failed to inhibit TACE (Fig. 4.5. B, C). Together these
results suggest that ceramide has no direct effect on TACE, but may influence its
activity by reorganizing the membrane bilayer and/or its intracellular localization.
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Such sensitivity of TACE to the lipid environment was also indicated by the
inhibitory effect that the addition of Triton X-100 to the TACE assay mixture had
on the measured activity (Fig. 4.5 D). To that extent, we also observed
differences in TACE sub-cellular localization between the two genotypes. While
in asm+/+ macrophages TACE was localized in a Golgi-like compartment in close
proximity to the nucleus, in asm-/- cells a uniform and diffused staining was
observed throughout the cell body (Fig. 4.6 B). Studies using quantitative realtime PCR revealed that asm-/- cells do not express higher levels of TACE mRNA
(Fig. 4.6 A), thus excluding the possibility that the genotype-specific difference in
activity and localization reflected differences in protein expression.
Surprisingly, TACE activity was not sensitive to stimulation with LPS.
However, this could be a consequence of the specific assay conditions because
the endogenous substrate, which is absent in the control-treated cells, but
abundant in the LPS-treated cells may be an efficient competitor for the
exogenous substrate during an in vitro assay.

Effects of ASMase deficiency on the sub-cellular distribution of TNF

Apparently, ASMase deficiency affected step(s) in the processing of
proTNF to the sTNF form. To directly monitor proTNF intracellular trafficking
to and from the plasma membrane, indirect immunofluorescence was employed.
This approach allowed the detection of substantial production of TNF inside the
cells, mostly in ER/Golgi compartment (in permeabilized cells), and an
accumulation at the plasma membrane (in non-permeabilized cells) in response
to stimulation with LPS (Fig. 4.7A, and B). However, several apparent differences
were noticeable in asm-/- macrophages: (i) Seemingly, more TNF was present
throughout the cytosol, and (ii) TNF-positive vesicular structures were detected
in a close proximity to the plasma membrane. Co-treatment with TAPI-1, a TACE
inhibitor, increased the number of these TNF positive vesicles in asm-/- but not
in asm+/+ cells (Fig. 4.7 A and Fig. 4.8 B). Therefore, these vesicular structures in
asm-/- cells most likely contained TNF designated for TACE-mediated cleavage.
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Having in mind that TACE activity was higher in the asm-/- macrophages, the fact
that TAPI-1 sensitive pool of TNF was present in asm-/- but not in asm+/+ cells
may indicate that more proTNF molecules were recycled back to the plasma
membrane and underwent TACE-mediated processing in the asm-/- cells than in
asm+/+ cells. To test this, cells were stained for EEA1, a marker for early
endosomes. Notably, asm-/- macrophages had a higher number of early
endosomes as compared to asm+/+ macrophages (Fig. 4.7 C, and Fig. 4.8 C),
indicative of more active recycling pathways. To test whether the endosomes are
indeed as a reservoir of proTNF for plasma membrane recycling, co-localization
studies were done. More TNF-positive vesicles co-localized with EEA1 in LPS
treated asm-/- cells as compared to asm+/+ cells (Fig. 4.8A, and B). The number of
these double-positive vesicles increased in the presence of TAPI-1 only in asm-/cells, but not in asm+/+ cells (Fig. 4.8 D). Treatment with ammonium chloride led
to a significant increase in both TNF-positive and double-positive cellular
compartments (Fig. 4.8 D). Importantly, the effects of ammonium chloride were
more pronounced in the asm+/+ than in asm-/- cells. Together these results
consistently show that the early endosomes contained proTNF that is salvaged
from lysosomal proteolysis and is destined for recycling and TACE-mediated
processing. ASMase activity plays an important role in partitioning proTNF
between these two pathways.

Effects of exogenous sphingomyelinase on TNF processing

To test whether ASMase and ceramide are directly involved in regulating
TNF recycling, rescue experiments were done. Asm-/- cells were treated with
exogenous sphingomyelinase to increase ceramide at the plasma membrane.
This was sufficient to bring the sTNF level close to those measured in asm+/+
cells (Fig. 4.9A, B). Furthermore, sphingomyelinase treatment also significantly
decreased the number of early endosomes detected in asm-/- cells (Fig. 4.9 C).
These results not only link SMase and ceramide to early endosomes biogenesis

59

but also reveal a correlation between the number of early endosomes and the
levels of sTNF released in response to LPS.

Genotype-specific differences in cytokine release in vivo

To determine the effect of ASMase deletion on TNF production in vivo,
litter-matched asm+/+ and asm-/- mice were injected with saline or LPS (5.8mg/kg
of body weight). TNF and IL-1 were undetectable in saline-injected mice of
both genotypes. The administration of LPS led to a sharp increase in serum
levels of both cytokines. However, in ASMase-deficient mice, serum TNF
reached concentrations that were 10 to 15 fold higher than those measured in
sera from asm+/+ mice (Fig. 4.10 A), while the levels of IL-1 (Fig. 4.10 B) and IL6 (data not shown) were similar for both genotypes. These data are in agreement
with the genotype-based differences in TNF secretion observed in isolated
peritoneal macrophages and indicate that ASMase deficiency has a specific
effect on the regulation of TNF in vivo.

D. Discussion

The results presented in this chapter provide evidence that ASMase and
ceramide regulate the rate of post-translational processing and secretion of
TNF after LPS stimulation.
Two distinct mechanisms seem to be involved. First, ASMase-derived
ceramide apparently functions as a negative regulator of TACE activity. This is
supported by the inhibition of TACE activity observed after the treatment of
macrophages with exogenous ceramide or bacterial SMase, both of which
increase ceramide content of the plasma membrane. Consistently, the intrinsic
activity of TACE was higher in asm-/- macrophages as compared to asm+/+ cells.
Most likely, ceramide and ASMase modulate TACE activity by changing the
membrane microenvironement of the enzyme, because ceramide was effective
only when added to cultured cells but not directly to the assay mixture. As
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discussed earlier, TACE is a transmembrane protein and, based on the complete
loss of activity observed in the presence of detergent, seems to require an intact
lipid environment for optimal activity. Notably, Tellier et al. found that the mature
form

of

TACE,

but

not

the

inactive

pro-form,

is

localized

in

the

sphingomyelin:cholesterol-rich domains and co-purifies with caveolin 1 and
flotilin-1. These authors further suggest that sequestration of TACE in the
sphingomyelin:cholesterol rafts is rate-limiting for its activity [120]. This is in
excellent agreement with our conclusion that ASMase and ceramide control a
rate-limiting step in TNF processing. It is of particular interest that treatment
with SMase that not only hydrolyses SM, thereby depleting the plasma
membrane of cholesterol, but also has an inhibitory effect of the endogenous
TACE. It seems likely that the elevated sphingomyelin (and cholesterol) in asm-/cells create a more “favorable” environment for TACE and, consequently, higher
activity. Second, a seemingly independent mode of regulation was revealed by
our indirect immunofluorescent studies.

These experiments suggest that

ASMase also has an affect on the fate of intracellular proTNF in peritoneal
macrophages. It has been proposed previously that proTNF that is not
immediately cleaved by TACE is internalized and either degraded in the
lysosomes or recycled back to the plasma membrane, where it can be utilized for
TACE-mediated cleavage. Our results strongly support such a scenario and
provide initial evidence that the partitioning of the non-processed TNF between
these two pathways is modulated and may have a profound effect on the levels
of TNF secreted in a response to particular stimulus.
Consistent with previous studies implicating ASMase in the dynamics of
vesicle fusion and fission during endocytosis, we also found that asm-/macrophages have increased the number of early endosomes consistent with a
defect in the endosome maturation to lysosomes. Furthermore, the increased colocalization of EEA1 and TNF provides evidence that in the absence of
ASMase, TNF is sequestered in the early endosomes and likely recycled back
to the plasma membrane and cleaved by TACE. Evidence for this comes from
the observation that the inhibition of TACE by TAPI-1 caused significant elevation
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in intracellular TNF as well as TNF/EEA1 co-localization only in the asm-/- but
not in asm+/+ cells. In contrast, in asm+/+ cells similar increases were observed in
the presence of ammonium chloride, indicating that a portion of intracellular
TNF, localized in the early endosomes undergoes TACE-mediated cleavage in
asm-/- cells, but lysosomal clearance in asm+/+ cells.
Membrane lipids and proteins are moved from the early endosomes back
to the cell surface via two main routes: the rab4-dependent fast recycling
pathway, and the rab11-mediated slow recycling pathway. Fibroblasts from
Niemann-Pick Disease Type A patients seem to lack the rab4-mediated
recycling, but exhibit a more active rab11-dependent pathway [136]. Therefore,
the latter could be responsible for the increased TNF recycling in asm-/- cells.
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Figure 4.1. Post-translational processing of TNF. TNF is initially
synthesized as 26kD precursor molecule (proTNF). It is selected as a specific
cargo of trans-Golgi vesicles, which fuse with rab11 recycling endosomes en
route to the plasma membrane. At the plasma membrane proTNF is cleaved by
TACE at its ectodomain to release the soluble 17kD mature form (sTNF). The
uncleaved proTNF is internalized and either degraded in the lysosomes or
recycled back to the plasma membrane. Abbreviations: TLR4, Toll-like receptor
4; RE, recycling endosomes; EE, early endosomes; LE, late endosomes.
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Primary peritoneal macrophages

Figure 4.2. Post-translational processing of TNF in primary peritoneal
macrophages. Peritoneal macrophages were isolated from asm+/+ and asm-/mice and treated with LPS (10ng/ml) for the indicated times in the presence or
absence of ammonium chloride (10mM). TNF levels were determined in cell
extracts (A, D) or medium (B, C, and E) by Western Blotting. Cyclophilin A levels
were used to control for uniform loading. For quantification purposes, the data
were shown as a ratio of the levels in the medium collected from asm-/- and
asm+/+ cells and are mean  s.d. of three independent experiments.
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RAW264.7 cells

Figure 4.3. Post-translational processing of TNF in RAW264.7 macrophage
cell line. RAW264.7 cells were stimulated with LPS (10ng/ml) for the indicated
time in the presence or absence of ammonium chloride (10mM). Where indicated
pre-treatment with desipramine (25M) was used to inhibit ASMase activity.
TNF levels were determined in cell extracts (B, C, E) or medium (A, and D) by
Western Blotting. Cyclophilin A levels were used to control for uniform loading.
For quantification purposes (C), the data were shown as a percent of the
maximum response and are mean  s.d. of two independent experiments.
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Figure 4.4. TACE activity in asm+/+ and asm-/- macrophages. A, B. Test for
linearity of TACE activity assay with protein and time. TACE activity
measured in vitro in detergent-free lysates prepared from RAW264.7 cells. C, D.
Effect of ASMase deficiency on activity of TACE. TACE activity is measured
in lysates from asm+/+ and asm-/- macrophages in vitro. Cells were treated with
saline (C) or LPS (10 ng/ml, D) for 4 hours. Activity is shown as a percent of the

66

maximum value measured in each set of experiments, which were 3907 RFU
and 3501 RFU for saline- and LPS-treated asm-/- macrophages, respectively. The
significance of the interaction effect is shown (###, p<0.001) based on two-way
ANOVA. E-H. Effect of sphingomyelinase and ceramide on TACE activity.
asm+/+ (E, G) and asm-/- (F, H) macrophages were treated with LPS (10ng/ml) for
4 hours in the presence of C2-ceramide (60M) (E, F), vehicle control (0.1%
ethanol) or bacterial sphingomyelinase (0.1units/ml) (G, H). TACE activity is
shown as percent of the value measured in vehicle-treated cells. The data are
mean  s.d. (n=3) and statistical significance of the treatment is shown (*,
p<0.05) based on student t-test.
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Figure 4.5. Effect of sphingolipids and detergent on TACE activity in vitro.
A-C Effect of Sphingolipids. TACE activity was measured in detergent-free
lysates from asm+/+ macrophages in the presence of C2-ceramide (A),
Dihydroceramide (B), and Sphingosine (C) added directly to the reaction mixture
of TACE activity assay. D. Effect of Detergent. TACE activity was measured in
lysates from asm+/+ macrophages in the presence (diamond) or absence (circle)
of Triton X-100. TACE activity is shown as percent of the value measured in
vehicle-treated cells.
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Figure 4.6. Expression and sub-cellular localization of TACE. A. TACE
mRNA levels. Macrophages from asm+/+ and asm-/- mice were isolated and
treated with LPS (10ng/ml) for the indicated time. TACE mRNA levels were
determined by real-time PCR and normalized to GAPDH mRNA in the same
sample.

The Data are presented as mean ± s.e.m. of three independent

experiments. Statistical significance of the treatment effect is shown (**, P<0.01;
*. P<0.05) based on two-way ANOVA. B. Visualization of TACE. The
localization of TACE in permeabilized asm+/+ and asm-/- was visualized using
antibodies against mouse TACE and fluorescent microscopy. Representative
image of three independent experiments is shown. Hoechst 33258 was used for
staining the nuclei. Scale bar represents 20m.
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Figure 4.7. Sub-cellular localization of TNF in asm+/+ and asm-/macrophages. Macrophages from asm+/+ and asm-/- mice were isolated and
treated with LPS (10ng/ml) in the presence and absence of TAPI-1 (20M) and
NH4Cl (10mM) for 4 hours. TNF was visualized in permeabilized (A) and nonpermeabilized (B) cells using antibodies against TNF and confocal microscopy.
The arrows indicate TNF-positive vesicles proximal to the plasma membrane
that are visible in asm-/- cells. Antibodies against the endosomal marker EEA1
were used to visualize early endosomes (C). Western blot analyses of the cell
culture medium that demonstrate the efficiency of the inhibitors (D). Transmitted
light images (B, C) show cells morphology. The scale bar represents 10m.
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Figure 4.8.

Co-localization of TNF and EEA1 in asm+/+ and asm-/-

macrophages. Peritoneal asm+/+ and asm-/- macrophages were treated with LPS
(10ng/ml) for 4 hours. Permeabilized cells were probed sequentially for TNF
(red) and EEA1 (green). Images were collected using confocal microscopy and
merged (yellow). Only merged images are shown and the TNF/EEA1 colocalization in a single cell for each panel is depicted by arrows. For
quantification purposes, the bulk fluorescence visible in the center of each cell
was excluded and the number of TNF (B)-, EEA1(C)- and double (D)-positive
vesicles (size bigger than 4 pixels) was counted in 10 cells of each slide. Data
shown are average  s.e.m. Statistical significance of the main effect (***<0.001;
**<0.01; *<0.05) and interaction effect (### < 0.001) was determined by two-way
ANOVA. The scale bar represents 20m.
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Figure 4.9. Effect of exogenous sphingomyelinase on sTNF and EEA1 in
asm-/- macrophages. Elicited peritoneal macrophages from asm+/+ and asm-/mice were treated for 4 hours with 10ng/ml LPS alone or in combination with
0.1units/ml bacterial sphingomyelinase. A. Levels of TNF in medium based
on Western blotting. B. Quantification of sTNF in the medium. The graph
represents the mean values  s.d. of intensity of TNF bands from three
independent

experiments.

C.

Visualization

of

the

early endosomes.

Immunofluorescent images depicting EEA1-positive early endosomes (green) in
permeabilized macrophages. Statistical significance of the main effect (**,
P<0.01) and the interaction effect of the treatment and the genotype (#, P<0.05)
are shown based on two-way ANOVA.
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Figure 4.10. Cytokine levels in LPS-injected asm+/+ and asm-/- mice.
Mice were injected i.p. with LPS (5.8mg/kg body weight) or saline. Serum was
collected at the indicated times and the levels of TNF (A) and IL-1 (B) were
measured by ELISA. Data for LPS-injected asm+/+ (filled circles) and asm-/- (open
circles) are shown. The levels of the cytokines in saline-injected animals were
below the detection levels. Data for individual animals are shown and are the
average of identical measurements done in triplicates. The group average 
s.e.m. is shown on the side. The significance of the main effects of genotype and
LPS (***, P<0.001; **, P<0.01; *, P<0.05) and the interaction effect (###,
P<0.001) is based on two-way ANOVA with Bonferroni post-test analysis. The
inserts are representation of the data from asm+/+ mice on a smaller scale.

Copyright © Krasimira Rozenova 2009
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CHAPTER FIVE

Conclusion

A. Summary of findings

This study provides evidence that ASMase and ceramide act as negative
regulators of LPS-induced TNF secretion both in vivo and in vitro.
Studies in isolated peritoneal macrophages showed that in ASMase
deficient cells LPS induced up to 3 fold higher levels of sTNF compared to the
control cells. Exogenous ceramide was sufficient to suppress TNF secretion
confirming the specificity of this effect.
Further mechanistic investigations in peritoneal macrophages as well as in
RAW264.7 macrophage cell line revealed that ASMase deficiency does not affect
the rate of IRAK-1 degradation and the activation pattern of ERK and JNK.
Moreover, the steady-state levels of TNF mRNA were not influenced by
ceramide or the lack of ASMase activity. Altogether, these results indicate that
ASMase affects step(s) of TNF production downstream of mRNA synthesis.
Detailed studies on the post-translational regulation of TNF secretion
further revealed that in macrophages post-translational processing is a major
determinant of the amount of sTNF secreted in response to LPS. Importantly,
for the first time it was demonstrated that a substantial amount of proTNF
undergoes proteolysis in an acidic compartment, most likely lysosomes, since
treatment with the lysosomotropic agent ammonium chloride caused a dramatic
acumulatin of proTNF in the cells. These results further suggest that the activity
of TACE is rate-limiting for the production of sTNF and is likely under tight
regulation.
Indeed, ASMase and ceramide seem to affect the cleavage of proTNF to
the bioactive mature form, sTNF, by acting as negative regulators of TACE
activity. Similarly to the effect on TNF secretion, ASMase deficiency was linked
to 3 fold increase in TACE activity and this effect was abolished after treatment
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with exogenous ceramide or bSMase. The exact mechanism by which ASMase
regulates TACE activity is not yet determined, however it seems likely that the
effect is on the localization of TACE rather than direct inhibition by ceramide.
An additional role of ASMase in the post-translational regulation of TNF
was also suggested by studies using indirect immunofluorescent: compared to
the control cells, in ASMase deficient macrophages more of the internalized
proTNF co-localizes with early endosomes. This genotype-based difference in
co-localization of TNF and EEA1 is exacerbated by the inhibition of TACE
mediated proTNF cleavage, but disappears after the addition of ammonium
chloride to block the lysosomal proteolisis of proTNF. Therefore, one plausible
interpretation of these results is that in asm-/- cells the lysosomal proteolysis of
TNF occurs at a slower rate compared to the asm+/+ cells, and instead proTNF
is redirected to the recycling pathway and delivered to the plasma membrane
where it can be re-used as a substrate for TACE and released as sTNF in the
medium. Such a scenario is in agreement with the detected higher TACE activity
in asm-/- cells, and explainsthe increased secretion of sTNF despite the lack of
genotype-based differences at the level of TNF mRNA.
It is unclear which of the two forms of ASMase is implicated in this
phenomenon. While the secretory form might be responsible for the regulation of
TACE activity at the plasma membrane, the lysosomal form might be linked to
the defects in endosomal maturation (Fig. 5.1.).
Finally, the parallel use of primary peritoneal macrophages and
RAW264.7 cell line throughout this study demonstrated that: (i) both cell models
responded to LPS stimulation in a similar fashion with regards to the activation of
MAP kinases and synthesis of TNF mRNA, however (ii) they differ substantially
in the post-translational processing of TNF, which might be a result of a
different rate of lysosomal proteolysis of uncleaved TNF. Therefore, RAW264.7
cells may not be a physiologically relevant model to study the mechanisms of
TNF post-translational regulation.

B. Future directions
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To decipher the mechanisms by which ASMase influences TACE activity

It has been demonstrated that ASMase and ceramide affect TACE activity,
thus it is of great interest to provide additional details regarding the mechanism
by which they exert their effects. The existing data suggest that the increased
activity in ASMase deficient cells is not a consequence of higher level of TACE
expression and most likely ceramide does not directly inhibit the enzyme.
However, the difference in the localization of TACE between genotypes and the
requirement of an intact membrane for optimal activity of TACE suggest that lipid
composition and distribution at the plasma membrane in asm-/- macrophages
may create more favorable environment for TACE activity. This hypothesis can
be tested initially by in situ TACE activity assay where the intact cell membranes
will be preserved and will reflect the differences in TACE activity found between
asm-/- and asm+/+ cells. Furthermore, in situ assay performed after cell treatment
with sphingomyelinase or cholesterol depleting agents will provide additional
insight about the role of sphingomylin:cholsterol enriched lipid domains for TACE
activity. A direct link between the increase in TACE activity and its localization
within lipid rafts can be established by the isolation of sphingomyelin:cholesterol
rich microdomains and measurement of TACE activity in rafts and non-rafts
fractions. The distribution of TACE within rafts and non-rafts fractions can be also
visualized in macrophages from asm+/+ and asm-/- mice by Western blotting .
Translocation of TACE within or out of lipid rafts has been suggested to
play a role in substrate selectivity. TNF is not the only substrate for TACE,
therefore it is of importance to determine whether the role of ASMase is limited to
TACE-mediated cleavage of TNF, or it if is a broader phenomenon and holds
true for other substrates as well. A number of studies implicate TACE in the
shedding of TGF, therefore measuring the levels of TGF in medium from asm/-

and asm+/+ will provide some insight about the effect of ASMase on substrate

selectivity of TACE.
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Investigate in further details the role of ASMase in determining the fate of
internalized proTNF

Another question to be addressed is the effect of ASMase deficiency on
the distribution of internalized TNF in cellular compartments involved in the
pathways for recycling and degradation. Evidence was provided that after
inhibition of TACE-mediated cleavage in asm-/- macrophages more TNF colocalizes with the marker for early endosome. This result together with the finding
that asm-/- have higher amount of early endosomes indicates that in ASMase
deficient cells the maturation of early endosomes to late endosomes and
lysosomes may be impaired and less TNF is subjected to lysosomal proteolysis.
Experiments for co-localization of TNF with markers of late endosomes and
lysosomes will provide further support for this hypothesis. Additionally, it is also
important to provide direct evidence that ASMase deficiency is linked to an
increased rate of TNF recycling to the plasma membrane and that internalized
and recycled proTNF is used for cleavage by TACE. Therefore, it is essential to
demonstrate increased co-localization of TNF with rab11 recycling vesicles in
macrophages from asm-/- cells compared to asm+/+ cells. To establish a direct link
between the rate of the recycling pathway and the amount of sTNF secreted in
the medium, studies with an overexpression of wild-type rab11 or dominant
negative form can be performed followed by Western blotting or ELISA to monitor
sTNF in the medium.

Physiological significance of the negative regulation of TNF production by
ASMase and ceramide

The diverse nature of pathogens and the enormous number of proteins
engaged in the host defense will lead to overwhelming immune response if it
were left unchecked. Therefore, TLR4 signaling is under tight negative
regulation, which is achieved at multiple levels and some key players have been
already identified. During acute bacterial infection the effective concentration of
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LPS is lowered after binding to the soluble TLR4, which appears to serve as
decoy receptor and prevents the interaction between TLR4 and other co-receptor
complexes, especially CD14 and MD-2, and will therefore terminate TLR4
signaling. However, once the interaction between cell surface TLR4 and LPS has
occurred, TLR4 signaling can be controlled by intracellular regulators. The
recruitment of a shorter version of MyD88 (MyD88s) ends the signal at the level
of TLR4 associated adaptor proteins [137]. Overexpression of MyD88s favors
formation of MyD88s-MyD88 heterodimers, in the presence of which IRAK-1 is
recruited but not phosphorylated [138]. Interestingly, MyD88s is inhibitory in
respect to NF-B signaling, but its overexpression does not prevent AP-1
activation, suggesting that it is important for the fine-tuning of TLR4 responses
[139]. Another candidate for negative regulator of TLR4 signaling is IRAKM,
which is induced by LPS and knockout mice for this molecule have enhanced
production of pro-inflammatory cytokines after stimulation with LPS. Similarly,
SOCS-1 deficient mice produce high levels of pro-inflammatory cytokines and
are highly susceptible to septic shock, suggesting that SOCS-1 is an important
player in negative feedback mechanism for regulation of TLR4-induced
responses. Interestingly, however, in none of the above mentioned examples has
the exact mechanisms by which these negative regulation occurs been fully
elucidated. It appears that some of the intracellular regulators are present
constitutively to control TLR4 activation at a physiological level, whereas others
are upregulated by TLR4 signaling during infection to attenuate the TLR4
response in a negative feedback loop. ASMase appears to fulfill the requirements
of the second type of negative regulators; (i) LPS stimulation leads to activation
of ASMase and generation of ceramide, (ii) a hallmark of the immune response
to LPS is TNF production, which in turn exerts strong pro-apoptotic effects on
various cell types, and (iii) TNF induced apoptosis is mediated by ASMasederived ceramide. Uncontrolled production of TNF clearly has deleterious
effects for the organism and is linked to high morbidity and mortality during septic
shock. Therefore, it is tempting to speculate that ASMase might serve as a
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sensor and it is a component of a negative feedback mechanism for regulation of
TNF levels.
Both forms of ASMase, secretory and lysosomal, are altered during the
onset of various diseases including cancer, obesity, and septic shock. One could
speculate that cellular ASMase activity and/or ceramide content might have a
more important role in regulating systemic inflammatory responses than
previously thought by affecting the magnitude of TNF release by the cells of the
immune system and other TNF-producing cells. Such a conclusion is supported
by studies demonstrating that patients with Niemann-Pick Disease are at high
risk of developing atherosclerosis, an inflammatory disease with a clear link to
TNF levels.
A variety of TACE substrates have been described with a broad spectrum
of biological activities; so the role of ASMase on TACE activity may not be limited
to TNF secretion and may have additional importance since the differential
regulation of TACE expression and activity has been demonstrated in conditions
such as cancer and cardiovascular disease. For example, an increase in TACE
expression has been found in breast cancer, ovarian carcinomas, and prostatic
carcinomas; and it was suggested to play an important role in tumor progression
via activation of HER4 ligands [140]. Furthermore, it has been shown that
activation of EGFR signaling during breast cancer progression was driven by
TACE [141]. Targeting TACE activity has been considered as a promising
therapeutic target in colorectal cancer [142]. Furthermore, abnormal TACE
activity has also been reported in cardiovascular diseases. For example, a
possible role of TACE on vascular complications of diabetes has been suggested
[143] and polymorphism of the TACE gene is linked to an increased risk of
cardiovascular

death
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[144].

Figure 5.1. Proposed mechanism for the role of ASMase in LPS-induced
TNF production.
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